Literature DB >> 29149259

Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data.

Vanessa L Gordon-Dseagu1, Susan S Devesa1, Michael Goggins2, Rachael Stolzenberg-Solomon1.   

Abstract

Background: Annual pancreatic cancer incidence rates have been increasing. We examine pancreatic cancer incidence trends by demographics and histologic type.
Methods: Data from the Surveillance, Epidemiology and End Results (SEER) registries were available to assess temporal trends and pancreatic cancer rates from 1974 to 2013.
Results: Pancreatic cancer incidence rates declined between the 1970s and 1990s but increased from 1994 to 2013 among White males. Among non-Hispanic White and Hispanic males, the annual percent change (APC) in incidence between 1992 and 2013 was 0.84% and 0.73%, respectively. Rates also rose among White non-Hispanic, Hispanic and Asian females (APC = 0.81%, 0.56% and 1.23%, respectively) and even more rapidly among females aged 25-34 years (APC > 2.5%). Rates among Black males and females remained unchanged, but higher compared with the other racial/ethnic groups. By histologic type, the increases were greatest for non-secretory endocrine cancers ( > 6%), followed by ductal adenocarcinomas (∼5%) and adenocarcinoma, NOS (∼1.4%)-the largest histologic subgroup of pancreatic cancer. Rates for mucinous adenocarcinomas and poorly specified pancreatic cancer decreased. Overall, incidence rates during 2000-13 were higher among males than females [MF incidence rate ratio (IRR) = 1.28]. The IRR was >1.00 at all ages ≥ 35, but rates among females were higher at younger ages (IRRs 15-24: 0.66, 25-34: 0.81). The MF IRRs for most of the histologic types were elevated among males apart from solid pseudopapillary adenocarcinoma and cystic carcinomas (IRR = 0.22, confidence interval: 0.14-0.34 and 0.52, 0.41-0.65, respectively).
Conclusion: Pancreatic cancer has been increasing overall, but patterns differ by demographic group and histologic type. Many of the trends parallel changing prevalence of lifestyle risk factors such as smoking, overweight and obesity, and diabetes in the USA, particularly for pancreatic adenocarcinoma, and improved diagnosis methods during the past 40 years.

Entities:  

Mesh:

Year:  2018        PMID: 29149259      PMCID: PMC5913617          DOI: 10.1093/ije/dyx232

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  39 in total

Review 1.  Nonductal Pancreatic Cancers.

Authors:  Sun-Young Jun; Seung-Mo Hong
Journal:  Surg Pathol Clin       Date:  2016-10-12

2.  Graphical presentation of trends in rates.

Authors:  S S Devesa; J Donaldson; T Fears
Journal:  Am J Epidemiol       Date:  1995-02-15       Impact factor: 4.897

3.  Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.

Authors:  Thorvardur R Halfdanarson; William R Bamlet; Robert R McWilliams; Timothy J Hobday; Patrick A Burch; Kari G Rabe; Gloria M Petersen
Journal:  Pancreas       Date:  2014-11       Impact factor: 3.327

4.  Solid pseudopapillary tumor of the pancreas: can malignancy be predicted?

Authors:  Chan Wook Kim; Duck Jong Han; Jihun Kim; Young Hoon Kim; Jae Berm Park; Song Cheol Kim
Journal:  Surgery       Date:  2011-05       Impact factor: 3.982

5.  Alcohol use and risk of pancreatic cancer: the NIH-AARP Diet and Health Study.

Authors:  Li Jiao; Debra T Silverman; Catherine Schairer; Anne C M Thiébaut; Albert R Hollenbeck; Michael F Leitzmann; Arthur Schatzkin; Rachael Z Stolzenberg-Solomon
Journal:  Am J Epidemiol       Date:  2009-03-18       Impact factor: 4.897

Review 6.  Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.

Authors:  Andrew E Becker; Yasmin G Hernandez; Harold Frucht; Aimee L Lucas
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

7.  Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study.

Authors:  Manal M Hassan; Alexandria Phan; Donghui Li; Cecile G Dagohoy; Colleen Leary; James C Yao
Journal:  Int J Cancer       Date:  2008-08-15       Impact factor: 7.396

8.  Why do Black Americans have a higher risk of pancreatic cancer than White Americans?

Authors:  Debra T Silverman; Robert N Hoover; Linda M Brown; G Marie Swanson; Mark Schiffman; Raymond S Greenberg; Richard B Hayes; Keith D Lillemoe; Janet B Schoenberg; Ann G Schwartz; Jonathan Liff; Linda M Pottern; Joseph F Fraumeni
Journal:  Epidemiology       Date:  2003-01       Impact factor: 4.822

Review 9.  A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.

Authors:  A Carrato; A Falcone; M Ducreux; J W Valle; A Parnaby; K Djazouli; K Alnwick-Allu; A Hutchings; C Palaska; I Parthenaki
Journal:  J Gastrointest Cancer       Date:  2015-09

10.  Global temporal patterns of pancreatic cancer and association with socioeconomic development.

Authors:  Martin C S Wong; Johnny Y Jiang; Miaoyin Liang; Yuan Fang; Ming Sze Yeung; Joseph J Y Sung
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

View more
  47 in total

1.  Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough?

Authors:  Ding Ding; Ammar A Javed; Chunhui Yuan; Michael J Wright; Zunaira N Javed; Jonathan A Teinor; I Chae Ye; Richard A Burkhart; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Gastrointest Surg       Date:  2020-02-05       Impact factor: 3.452

2.  Age-standardized cancer-incidence trends in Canada, 1971-2015.

Authors:  Darren R Brenner; Yibing Ruan; Eileen Shaw; Dylan O'Sullivan; Abbey E Poirier; Emily Heer; Paul J Villeneuve; Stephen D Walter; Christine M Friedenreich; Leah Smith; Prithwish De
Journal:  CMAJ       Date:  2019-11-18       Impact factor: 8.262

3.  Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Francisca Beato; Dayana Reverón; Kaleena B Dezsi; Antonio Ortiz; Joseph O Johnson; Dung-Tsa Chen; Karla Ali; Sean J Yoder; Daniel Jeong; Mokenge Malafa; Pamela Hodul; Kun Jiang; Barbara A Centeno; Mahmoud A Abdalah; Jodi A Balasi; Alexandra F Tassielli; Bhaswati Sarcar; Jamie K Teer; Gina M DeNicola; Jennifer B Permuth; Jason B Fleming
Journal:  Lab Invest       Date:  2020-10-09       Impact factor: 5.662

Review 4.  Small molecule inhibitors in pancreatic cancer.

Authors:  Jufeng Sun; Cecilia C Russell; Christopher J Scarlett; Adam McCluskey
Journal:  RSC Med Chem       Date:  2020-01-24

Review 5.  Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.

Authors:  Mark B Ulanja; Alastair E Moody; Bryce D Beutler; Daniel Antwi-Amoabeng; Ganiyu A Rahman; Olatunji B Alese
Journal:  Oncotarget       Date:  2022-06-15

6.  Diagnostic delay does not influence survival of pancreatic cancer patients.

Authors:  Caterina Stornello; Livia Archibugi; Serena Stigliano; Giuseppe Vanella; Benedetta Graglia; Carlo Capalbo; Giuseppe Nigri; Gabriele Capurso
Journal:  United European Gastroenterol J       Date:  2019-09-19       Impact factor: 4.623

7.  Differences in Pancreatic Cancer Incidence Rates and Temporal Trends Across Asian Subpopulations in California (1988-2015).

Authors:  Lihua Liu; Juanjuan Zhang; Dennis Deapen; Mariana C Stern; Andrea Sipin; Stephen J Pandol; Veronica Wendy Setiawan
Journal:  Pancreas       Date:  2019-08       Impact factor: 3.243

8.  Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3.

Authors:  Evelina Mocci; Prosenjit Kundu; Nilanjan Chatterjee; Alison P Klein; Rachael Stolzenberg-Solomon; William Wheeler; Alan A Arslan; Laura E Beane-Freeman; Paige M Bracci; Paul Brennan; Federico Canzian; Mengmeng Du; Steven Gallinger; Graham G Giles; Phyllis J Goodman; Charles Kooperberg; Loic Le Marchand; Rachel E Neale; Xiao-Ou Shu; Kala Visvanathan; Emily White; Wei Zheng; Demetrius Albanes; Gabriella Andreotti; Ana Babic; William R Bamlet; Sonja I Berndt; Amanda L Blackford; Bas Bueno-de-Mesquita; Julie E Buring; Daniele Campa; Stephen J Chanock; Erica J Childs; Eric J Duell; Charles S Fuchs; J Michael Gaziano; Edward L Giovannucci; Michael G Goggins; Patricia Hartge; Manal M Hassan; Elizabeth A Holly; Robert N Hoover; Rayjean J Hung; Robert C Kurtz; I-Min Lee; Núria Malats; Roger L Milne; Kimmie Ng; Ann L Oberg; Salvatore Panico; Ulrike Peters; Miquel Porta; Kari G Rabe; Elio Riboli; Nathaniel Rothman; Ghislaine Scelo; Howard D Sesso; Debra T Silverman; Victoria L Stevens; Oliver Strobel; Ian M Thompson; Anne Tjonneland; Antonia Trichopoulou; Stephen K Van Den Eeden; Jean Wactawski-Wende; Nicolas Wentzensen; Lynne R Wilkens; Herbert Yu; Fangcheng Yuan; Anne Zeleniuch-Jacquotte; Laufey T Amundadottir; Donghui Li; Eric J Jacobs; Gloria M Petersen; Brian M Wolpin; Harvey A Risch; Peter Kraft
Journal:  Cancer Res       Date:  2021-02-11       Impact factor: 13.312

9.  Cruciferous vegetable consumption and pancreatic cancer: A case-control study.

Authors:  Maia E W Morrison; Emma G Hobika; Janine M Joseph; Ashley E Stenzel; Jennifer M Mongiovi; Li Tang; Susan E McCann; James Marshall; Christos Fountzilas; Kirsten B Moysich
Journal:  Cancer Epidemiol       Date:  2021-03-11       Impact factor: 2.890

10.  Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Felix C Popp; Ingracia Capino; Joana Bartels; Alexander Damanakis; Jiahui Li; Rabi R Datta; Heike Löser; Yue Zhao; Alexander Quaas; Philipp Lohneis; Christiane J Bruns
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.